Sarcoidosis echocardiography or ultrasound

Revision as of 13:39, 6 May 2018 by Roshan (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Sarcoidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Sarcoidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sarcoidosis echocardiography or ultrasound On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sarcoidosis echocardiography or ultrasound

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sarcoidosis echocardiography or ultrasound

CDC on Sarcoidosis echocardiography or ultrasound

Sarcoidosis echocardiography or ultrasound in the news

Blogs on Sarcoidosis echocardiography or ultrasound

Directions to Hospitals Treating Sarcoidosis

Risk calculators and risk factors for Sarcoidosis echocardiography or ultrasound

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Roshan Dinparasti Saleh M.D.

Overview

Infiltrative cardiomyopathy caused by sarcoidosis, has two major complications: arrhythmias, and reduced ejection fraction. Therefore echocardiography and 24-48 hour cardiac monitoring are useful tests for screening of cardiac involvement.

Ultrasound

Infiltrative cardiomyopathy caused by sarcoidosis, has two major complications: arrhythmias, and reduced ejection fraction. Therefore echocardiography and 24-48 hour cardiac monitoring are useful tests for screening of cardiac involvement.[1][2]

References

  1. Hamzeh NY, Wamboldt FS, Weinberger HD: Management of cardiac sarcoidosis in the United States: a Delphi study. Chest 2012, 141(1):154-162.
  2. Mehta D, Lubitz SA, Frankel Z, et al: Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 133(6):1426–1435, 2008.

Template:WH Template:WS